Goldman Sachs Downgrades Nektar Therapeutics (NKTR) to Sell
Tweet Send to a Friend
Goldman Sachs analyst Chris Shibutani downgraded Nektar Therapeutics (NASDAQ: NKTR) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
